North Star Asset Management Inc. bought a new stake in Henry Schein, Inc. (NASDAQ:HSIC – Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 6,985 shares of the company’s stock, valued at approximately $583,000.
Other large investors also recently bought and sold shares of the company. Public Employees Retirement System of Ohio purchased a new stake in Henry Schein during the second quarter valued at $2,547,000. Redwood Investment Management LLC purchased a new position in shares of Henry Schein in the 2nd quarter worth $1,167,000. Foyston Gordon & Payne Inc bought a new stake in shares of Henry Schein in the 2nd quarter worth about $6,304,000. Foster & Motley Inc. purchased a new stake in shares of Henry Schein during the 2nd quarter valued at about $579,000. Finally, Buckland Partners Management Co LLC purchased a new stake in shares of Henry Schein during the 2nd quarter valued at about $1,036,000. Institutional investors own 96.62% of the company’s stock.
Analyst Ratings Changes
Several research firms have recently issued reports on HSIC. Mizuho lowered their price objective on Henry Schein from $88.00 to $82.00 and set a “neutral” rating for the company in a research note on Wednesday, May 6th. UBS Group set a $94.00 target price on shares of Henry Schein and gave the stock a “neutral” rating in a report on Wednesday, August 5th. Citigroup reaffirmed a “buy” rating and set a $112.00 price target (up from $100.00) on shares of Henry Schein in a research note on Wednesday, August 5th. BMO Capital Markets started coverage on shares of Henry Schein in a report on Wednesday, July 8th. They set a “market perform” rating and a $85.00 price target on the stock. Finally, Barclays reissued an “overweight” rating and issued a $100.00 price objective (up from $86.00) on shares of Henry Schein in a research report on Thursday, August 6th. Nine investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $92.93.
Henry Schein Trading Down 0.8%
NASDAQ HSIC opened at $89.52 on Friday. The stock has a market cap of $9.98 billion, a PE ratio of 26.10, a PEG ratio of 1.72 and a beta of 0.80. Henry Schein, Inc. has a 12 month low of $61.94 and a 12 month high of $92.18. The company’s 50-day moving average price is $86.68 and its 200-day moving average price is $80.00. The company has a current ratio of 1.32, a quick ratio of 0.73 and a debt-to-equity ratio of 0.60.
Henry Schein (NASDAQ:HSIC – Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $1.27 earnings per share for the quarter, beating analysts’ consensus estimates of $1.24 by $0.03. The company had revenue of $3.46 billion during the quarter, compared to analyst estimates of $3.37 billion. Henry Schein had a net margin of 2.96% and a return on equity of 15.97%. The firm’s revenue for the quarter was up 6.7% on a year-over-year basis. During the same quarter last year, the business posted $1.10 EPS. Henry Schein has set its FY 2026 guidance at 5.290-5.390 EPS. Equities research analysts forecast that Henry Schein, Inc. will post 5.36 earnings per share for the current year.
About Henry Schein
Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.
In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.
See Also
- Five stocks we like better than Henry Schein
- 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
- IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
- Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude?
- Okta Stock Surges 29%—Is $200 the Next Stop?
Want to see what other hedge funds are holding HSIC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Henry Schein, Inc. (NASDAQ:HSIC – Free Report).
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.
